Inhibitors of extracellular HSP90
The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells.
1. An assay for selecting a subject with invasive or metastatic cancer to be treated with a Hsp90 inhibitor treatment, wherein the Hsp90 inhibitor treatment is an anti-Hsp90 antibody or fragment thereof which binds to human extracellular Hsp90, the assay comprising:
a. subjecting a biopsy sample from the subject to immunohistological staining with an antibody or antibody fragment that binds to human extracellular Hsp90
b. measuring the binding of the antibody or antibody fragment to human extracellular Hsp90 on the surface of cells in the biopsy sample; and
c. selecting the subject with invasive or metastatic cancer to be treated with the Hsp90 inhibitor treatment where the immunohistological staining shows localization of the antibody or antibody fragment that binds to human extracellular Hsp90 on the surface of cells in the biopsy sample.
2. The assay of claim 1 , wherein the antibody or antibody fragment is a monoclonal antibody.
3. The assay of claim 1 , wherein the antibody or antibody fragment is unable to enter a cell.
4. The assay of claim 1 , wherein the antibody or antibody fragment is labelled with a detectable label.
5. The assay of claim 1 , wherein the antibody or antibody fragment is recombinantly produced antibody or antibody fragment.
6. The assay of claim 1 , wherein the antibody or antibody fragment is a humanized antibody or antibody fragment.
7. The assay of claim 1 , wherein the antibody or antibody fragment is a human antibody or antibody fragment.
8. The assay of claim 7 , wherein the human antibody or antibody fragment is a human monoclonal antibody.
9. The assay of claim 1 , wherein the cancer is selected from the group consisting of; breast adenocarcinoma, melanoma, fibrosarcoma.
10. The assay of claim 1 , wherein the antibody or antibody fragment is an anti-Hsp90α antibody or antibody fragment.
11. The assay of claim 1 , wherein the cancer is a solid tumor.
12. The assay of claim 1 , further comprising administering an anti-Hsp90 antibody or antibody fragment which binds to human extracellular Hsp90 to the subject selected to be treated with the Hsp90 inhibitor treatment.